Endocrinopathy of HFE-related hemochromatosis

References

• Von Recklinghausen FD. Uber Haemochromatose Heidelberg. Taggelblatt der Versammlung deutscher Naturforscher und Aerzte in Heidelberg.62, 324–325 (1889).
   Google Scholar
• Sheldon JH. Haemochromatosis. London, Oxford University Press (1935).
   Google Scholar
• Simon M, Bourel M, Fauchet R, Genetet B. Association of HLA-A3 and HLA-B14 antigens with idiopathic haemochromatosis Gut7, 332–334 (1976).
   Google Scholar
• Feder JN, Gnirke A, Thomas W et al. A novel MHC Class I-like gene is mutated in patients with hereditary haemochromatosis. Nat. Genet.13(4), 399–408 (1996).
   PubMed Web of Science ®Google Scholar
• Byrnes V, Ryan E, Barrett S, Kenny P, Mayne P, Crowe J. Genetic haemochromatosis, a Celtic disease: is it now time for population screening? Genet. Test.5(2), 127–130 (2001).
   Google Scholar
• Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJ. Global prevalence of putative haemochromatosis mutations. J. Med. Genet.34, 275–278 (1997).
   PubMed Web of Science ®Google Scholar
• Adams PC, Reboussin DM, Barton JC et al. The hemochromatosis and iron overload screening study research investigators: hemochromatosis and iron-overload screening in a racially diverse population. N. Engl. J. Med.352, 1769–1778 (2005).
   PubMed Web of Science ®Google Scholar
• Beutler E. Hemochromatosis: Genetics and pathophysiology. Annu. Rev. Med.57, 331–347 (2006).
   Google Scholar
• Pietrangelo A. Molecular insights into the pathogenesis of hereditary haemochromatosis. Gut55, 564–568 (2006).
   PubMedGoogle Scholar
• Walsh CH. Non-diabetic endocrinopathy in hemochromatosis. In: Hemochromatosis. Barton JC, Edwards CQ (Ed.). Cambridge University Press, UK, 278–289 (2000).
   Google Scholar
• MacDonald RA, Mallory GK. Hemochromatosis and hemosiderosis: study of 211 autopsied cases. Arch. Int. Med.105, 52–66 (1960).
   Google Scholar
• Rahier JR, Loozen S, Goebbels RM, Abrahem M. The haemochromatotic human pancreas: a quantitative immunohistochemical and ultrastructural study. Diabetologia30, 5–12 (1987).
   Google Scholar
• Merkel PA, Simonson DC, Amiel SA et al. Insulin resistance and hyperinsulinaemia in patients with thalassemia major treated by hypertransfusion. N. Engl. J. Med.318, 809–814 (1988).
   PubMed Web of Science ®Google Scholar
• Hramiak IM, Finegood DT, Adams PC. Factors affecting glucose tolerance in hereditary hemochromatosis. Clin. Invest. Med.20(2), 110–118 (1997).
   PubMed Web of Science ®Google Scholar
• Buysschaert M, Paris I, Selvais P, Hermans MP. Clinical aspects of diabetes secondary to idiopathic haemochromatosis in French-speaking Belgium. Diabetes Metab.23(4), 308–313 (1997).
   Google Scholar
• Cooksey RC, Jouihan HA, Ajioka RS et al. Oxidative stress, β-cell apoptosis, and decreased insulin secretory capacity in mouse models of hemochromatosis. Endocrinology145, 5305–5312 (2004).
   PubMed Web of Science ®Google Scholar
• McClain DA, Abraham D, Rogers J et al. High prevalence of abnormal glucose homeostasis secondary to decreased insulin secretion in individuals with hereditary haemochromatosis. Diabetologia49, 1661–1669 (2006).
   PubMed Web of Science ®Google Scholar
• Tuomainen TP, Nyyssonen K, Salonen R et al. Body iron stores are associated with serum insulin and blood glucose concentrations: population study in 1,013 eastern Finnish men. Diabetes Care20, 426–428 (1997).
   PubMed Web of Science ®Google Scholar
• Salonen JT, Tuomainen TP, Nyyssonen K, Lakka HM, Punnonen K. Relation between iron stores and non-insulin dependent diabetes in men: case-control study. Br. Med. J.317, 727 (1998).
   PubMedGoogle Scholar
• Ford ES, Cogswheel ME. Diabetes and serum ferritin concentration among U.S. adults. Diabetes Care22(12), 1978–1983 (1999).
   PubMed Web of Science ®Google Scholar
• Ascherio A, Rimm EB, Giovannucci E, Willett WC, Stampfer MJ. Blood donations and risk of coronary heart disease in men. Circulation103, 52–57 (2001).
   PubMed Web of Science ®Google Scholar
• Jiang R, Ma J, Ascherio A, Stampfer MJ, Willett WC, Hu FB. Dietary intake and blood donations in relation to risk of Type 2 diabetes in men: a prospective cohort study. Am. J. Clin. Nutr.79(1), 70–75 (2004).
   PubMed Web of Science ®Google Scholar
• Fernandez-Real JM, Penarroja G, Castro A, Garcia-Bragado F, Hernandez-Aguado I, Ricart W. Blood letting in high-ferritin Type 2 diabetes: effects on insulin sensitivity and β-cell function. Diabetes51, 1000–1004 (2002).
   PubMed Web of Science ®Google Scholar
• Fernandez-Real JM, Penarroja G, Castro A, Garcia-Bragado F, Lopez-Bermejo A, Ricart W. Blood letting in high-ferritin type 2 diabetes: effects on vascular reactivity. Diabetes Care25(12), 2249–2255 (2002).
   Google Scholar
• Jiang R, Manson JE, Meigs JB, Ma J, Rifai N, Hu FB. Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. J. Am. Med. Assoc.291(6), 711–717 (2004).
   PubMed Web of Science ®Google Scholar
• Jehn M, Clark JM, Gualler E. Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care27(10), 2422–2428 (2004).
   PubMed Web of Science ®Google Scholar
• Wrede CE, Buettner R, Bollheimer LC, Scholmerich J, Palitzsch KD, Hellerbrand C. Association between serum ferritin and the insulin resistance syndrome in a representative population. Eur. J. Endocrinol.154(2), 333–340 (2006).
   PubMed Web of Science ®Google Scholar
• Chen X, Scholl TO, Stein TP. Association of elevated serum ferritin levels and the risk of gestational diabetes in pregnant women: the Camden study. Diabetes Care29(5), 1077–1182 (2006).
   PubMed Web of Science ®Google Scholar
• Wolff SP. Diabetes Mellitus and free radicals: free radicals, transition metals oxidative stress in the aetiology of diabetes mellitus and complications. Br. Med. Bull.49(3), 642–652 (1993).
   PubMed Web of Science ®Google Scholar
• Eaton JW, Qian M. Molecular bases of cellular iron toxicity. Free Radic. Biol. Med.32(9), 833–840 (2002).
   PubMed Web of Science ®Google Scholar
• Wiederkehr A, Wollheim CB. Minireview: implication of mitochondria in insulin secretion and action. Endocrinology147(6), 2643–2649 (2006).
   PubMed Web of Science ®Google Scholar
• Iwasaki T, Nakajima A, Yoneda M et al. Serum ferritin is associated with visceral fat area and subcutaneous fat area. Diabetes Care28(10), 2486–2491 (2005).
   PubMed Web of Science ®Google Scholar
• O’Sullivan EP, McDermott JH, Sen S, Walsh CH. Diabetes mellitus in hereditary haemochromatosis – 23 years experience in a single centre. Ir. J. Med. Sci.175(4), 25 (2006).
   Google Scholar
• Bezwoda WR, Bothwell TH, Van Der Walt LA, Kronheim S, Pimstone BL. An investigation into gonadal dysfunction in patients with idiopathic haemochromatosis. Clin. Endocrinol. (Oxf.)6(5), 377–385 (1997).
   Google Scholar
• Lufkin EG, Baldus WP, Bergstralh EJ, Kao PC. Influence of phlebotomy treatment on abnormal hypothalamic-pituitary function in genetic hemochromatosis. Mayo Clin. Proc.62(6), 473–479 (1987).
   Google Scholar
• Walton C, Kelly WF, Laing I, Bullock DE. Endocrine abnormalities in idiopathic haemochromatosis.haemochromatosis. Q. J. Med.52(205), 99–110 (1983).
   Google Scholar
• Charbonnel B, Chupin M, LeGrand A, Guillon J. Pituitary function in idiopathic haemochromatosis: hormonal study in 36 male patients. Acta Endocrinol. (Copenh.)98(2), 178–83 (1981).
   Google Scholar
• Peillon F, Radadot J. Modifications histopathologiques de l’hypophyse dans six cas d’hemochromatose. Ann. d’Endocrinol. (Paris)30, 800–807 (1969).
   Google Scholar
• Bergeron C, Kovacs K. Pituitary siderosis a histologic, immunocytologic, and ultrastructural study. Am. J. Pathol.93, 295–310 (1978).
   Google Scholar
• Tourniaire J, Fevre M, Mazenod B, Ponsin G. Effects of clomiphene citrate and synthetic LHRH on serum luteinizing hormone (LH) in men with idiopathic hemochromatosis. J. Clin. Endocrinol. Metab.38(6), 1122–1124 (1974).
   Google Scholar
• Siminoski K, D’Costa M, Walfish PG. Hypogonadotropic hypogonadism in idiopathic hemochromatosis: evidence for combined hypothalamic and pituitary involvement. J. Endocrinol. Invest.13, 849–853 (1990).
   PubMedGoogle Scholar
• Piperno A, Rivolta MR, D’Alba R et al. Preclinical hypogonadism in genetic hemochromatosis in the early stage of the disease: evidence of hypothalamic dysfunction. J. Endocrinol. Invest.15, 423–428 (1992).
   Google Scholar
• Duranteau L, Chanson P, Blumbberg-Tick J et al. Non-responsiveness of serum gonadotropins and testosterone to pulsatile GnRH in hemochromatosis suggesting a pituitary defect. Acta Endocrinol.128, 351–354 (1993).
   Google Scholar
• Walsh CH, Wright AD, Williams JW, Holder G. A study of pituitary function in patients with idiopathic hemochromatosis. J. Clin. Endocrinol. Metab.43(4), 866–872 (1976).
   Google Scholar
• Snyder PJ, Rudenstein RS, Gardner DF, Rothman JG. Repetitive infusion of gonadotropin-releasing hormone distinguishes hypothalamic from pituitary hypogonadism. J. Clin. Endocrinol. Metab.48, 864–868 (1979).
   PubMedGoogle Scholar
• McDermott JH, Walsh CH. Hypogonadism in Hereditary Hemochromatosis. J. Clin. Endocrinol. Metab.90(4), 2451–2455 (2005).
   PubMedGoogle Scholar
• Kelly TM, Edwards CQ, Meikle AW, Kushner JP. Hypogonadism in hemochromatosis: reversal with iron depletion. Ann. Intern. Med.101, 629–632 (1984).
   PubMedGoogle Scholar
• Cundy T, Butler J, Bomford A, Williams R. Reversibility of hypogonadotrophic hypogonadism associated with genetic haemochromatosis. Clin. Endocrinol. (Oxf.)38(6), 617–620 (1993).
   Google Scholar
• Stocks AE, Martin FIR. Pituitary function in haemochromatosis. Am. J. Med.45(6), 839–845 (1968).
   Google Scholar
• Iyer R, Duckworth WC, Solomon SS. Hypogonadism in idiopathic hemochromatosis. Endocrine studies. Arch. Int. Med.141(4), 517–518 (1981).
   Google Scholar
• Barton JC, Edwards CQ, Bertoli LF, Shroyer TW, Hudson SL. Iron overload in African Americans. Am. J. Med.99, 616–623 (1995).
   PubMed Web of Science ®Google Scholar
• Cundy T, Bomford A, Butler J, Wheeler M, Williams R. Hypogonadism and sexual dysfunction in hemochromatosis: the effects of cirrhosis and diabetes. J. Clin. Endocrinol. Metab.69(1), 110–116 (1989).
   Google Scholar
• O’Sullivan EP, McDermott JH, Walsh CH. All that is hypogonadal in haemochromatosis is not due to iron deposition. Ir. J. Med. Sci. (2006) (In Press).
   Google Scholar
• Siemons LJ, Mahler CH. Hypogonadotropic hypogonadism in hemochromatosis: recovery of reproductive function after iron depletion. J. Clin. Endocrinol. Metab.65(3), 585–587 (1987).
   PubMed Web of Science ®Google Scholar
• Gama R, Smith MJ, Wright J, Marks V. Hypopituitarism in primary haemochromatosis: recovery after iron depletion. Postgrad. Med. J.71, 297–298 (1995).
   Google Scholar
• Kley HK, Stremmel W, Kley JB, Schlaghecke R. Testosterone treatment of men with idiopathic hemochromatosis. Clin. Invest.70, 566–572 (1992).
   Google Scholar
• Selvais PL, Henrion J. Successful treatment by gonadotrophins of a patient with genetic haemochromatosis and infertility. Postgrad. Med. J.69, 241–242 (1993).
   Google Scholar
• Farina G, Pedrotti C, Cerani P et al. Successful pregnancy following gonadotrophin therapy in a young female with juvenile idiopathic haemochromatosis and secondary hypogonadotrophic hypogonadism. Haematology88, 335–337 (1995).
   Google Scholar
• Bricaire H, Guillon J, Leprat J, Modigliani-Kourilsky E. Le syndrome endocrinien des hemochromatoses idiopathiques. Soc. Med. Des Hopt. De Paris117, 909–928 (1966).
   Google Scholar
• McNeil LW, McKee LC Jr, Lorber D, Rabin D. The endocrine manifestations of hemochromatosis. Am. J. Med. Sci.285(3), 7–13 (1983).
   Google Scholar
• Hempenius LMC, Van Dam PS, Marx JJM, Koppeschaar HPF. Mineralocorticoid status and endocrine dysfunction in severe hemochromatosis. J. Endocrinol. Invest.22, 369–376 (1999).
   Google Scholar
• Walsh CH, Murphy AL, Cunningham S, McKenna TJ. Mineralocorticoid and glucocorticoid status in idiopathic haemochromatosis. Clin. Endocrinol. (Oxf.)41(4), 439–443 (1994).
   Google Scholar
• Thomas JP. Aldosterone deficiency in a patient with idiopathic haemochromatosis. Clin. Endocrinol. (Oxf.)21, 271–277 (1984).
   Google Scholar
• Charbonnel B, Chupin M, Lucas B, Chupin F, Guillon J. Adrenocortical function in idiopathic haemochromatosis. Acta Endocrinol. (Copenh.)95(1), 67–70 (1980).
   Google Scholar
• Milder MS, Cook JD, Stray S, Finch CA. Idiopathic hemochromatosis, an interim report. Medicine (Baltimore)59(1), 34–49 (1980).
   PubMed Web of Science ®Google Scholar
• Murphy MS, Walsh CH. Thyroid function in haemochromatosis. Ir. J. Med. Sci.173(1), 27–29 (2004).
   Google Scholar
• Edwards CQ, Kelly TM, Ellwein G, Kushner JP. Thyroid disease in haemochromatosis. Increased incidence in homozygous men. Arch. Int. Med.143, 1890–1893 (1983).
   Google Scholar
• Mautalen CA, Kvicala R, Perriard D, Bugnard E, Rossi E, Duhart J. Hypoparathyroidism and iron storage disease. Treatment with 25-hydroxy-vitamin D3. Am. J. Med. Sci.276(3), 363–368 (1978).
   Google Scholar
• Diamond T, Stiel D, Posen S. Osteoporosis in hemochromatosis: iron excess, gonadal deficiency, or other factors? Ann. Intern. Med.110(6), 430–436 (1989).
   Google Scholar
• Guggenbuhl P, Deugnier Y, Boisdet JF et al. Bone mineral density in men with genetic hemochromatosis and HFE gene mutation. Osteoporos Int.16(12), 1809–1814 (2005).
   PubMed Web of Science ®Google Scholar
• Dymock IW, Cassar J, Pyke DA, Oakley WG, Williams R. Observations on the pathgenesis, complications and treatment of diabetes in 115 cases of haemochromatosis. Am. J. Med.52(2), 203–210 (1972).
   PubMed Web of Science ®Google Scholar
• Milder MS, Cook JD, Stray S, Finch CA. Idiopathic hemochromatosis, an interim report. Medicine (Baltimore)59(1), 34–49 (1980).
   PubMed Web of Science ®Google Scholar
• Niederau C, Strohmeyer G, Stremmel W. Epidemiology, clinical spectrum and prognosis of hemochromatosis. Adv. Exp. Med. Biol.356, 293–302 (1994).
   PubMedGoogle Scholar
• Moirand R, Adams PC, Bicheler V, Brissot P, Deugnier Y. Clinical features of genetic hemochromatosis in women compared with men. Ann. Intern. Med.127(2), 105–110 (1997).
   PubMed Web of Science ®Google Scholar